^
    Back
    Association details:
    Biomarker:EGFR L858R
    Cancer:Glioblastoma
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) +
    temozolomide (DNA synthesis inhibitor) +
    Ameile (aumolertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Oncologist
    Title:

    Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation

    Published date:
    03/13/2023
    Excerpt:
    Interestingly, we identified an EGFR p.L858R mutation in a patient with recurrent GBM for the first time. Based on the genetic testing results, almonertinib combined with anlotinib and temozolomide was administered and obtained 12 months of progression-free survival after the diagnosis of recurrence as the fourth-line treatment.
    DOI:
    10.1093/oncolo/oyac280